|
Jul 16
|
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
|
|
Jul 14
|
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
|
|
Jul 14
|
NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox
|
|
Jul 1
|
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
|
|
May 28
|
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
|
|
May 16
|
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
|
|
May 15
|
NanoViricides: Fiscal Q3 Earnings Snapshot
|
|
Mar 11
|
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
|
|
Feb 19
|
NanoViricides, Inc. Has Filed its Quarterly Report
|
|
Feb 14
|
NanoViricides: Fiscal Q2 Earnings Snapshot
|
|
Feb 14
|
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?
|
|
Feb 11
|
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
|
|
Sep 30
|
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
|
|
Sep 26
|
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
|
|
Aug 26
|
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
|
|
Jul 24
|
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
|
|
Jul 11
|
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
|
|
Jun 24
|
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
|
|
Jun 11
|
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
|
|
May 15
|
NanoViricides Has Filed its Quarterly Report
|